作者: Mischa Roland Müller , Ronan O’Dwyer , Marina Kovaleva , Fiona Rudkin , Helen Dooley
DOI: 10.1007/978-1-61779-974-7_9
关键词:
摘要: The drive to exploit novel targets and biological pathways has lead the expansion of classical antibody research into innovative fragment adaptations scaffolds. hope being that alternative or cryptic epitopes may be targeted, tissue inaccessibility overcome, easier engineering options will facilitate multivalent, multi-targeting approaches. To this end, we have been isolating shark single domains gain a greater understanding their potential as therapeutic agents. Their unique shape, small size, inherent stability, simple molecular architecture make them attractive candidates from drug discovery perspective. Here describe protocols capture immune repertoire an immunized species build select via phage-display target-specific IgNAR variable (VNARs).